Tuesday 13 May, 2025 07:53 PM
Site map | Locate Us | Login
   Tata Motors Q4 PAT drops 52% YoY to Rs 8,470 cr; declares dividend of Rs 6 /sh    KFin Tech drops after block deals    Hero Motocorp gains after Q4 PAT climbs 6% YoY to Rs 1,081 cr    Cipla registers PAT of Rs 1,222 crore in Q4; EBITDA margin rises to 22.8%    Tata Steel Q4 PAT zooms 113% YoY to Rs 1,301 cr    Aether Industries Ltd leads losers in 'A' group    Ambica Agarbathies Aroma & Industries Ltd leads losers in 'B' group    TD Power Systems jumps after Q4 PAT climbs 83% YoY to Rs 53 cr    IIFL Finance climbs as foreign broker upgrades to 'buy'    Patel Engg slides after Q4 PAT drops 73% YoY to Rs 33 cr    Volumes soar at JM Financial Ltd counter    India Ratings affirms ratings of SBFC Finance at 'AA-' with 'stable' outlook    Information Technology stocks slide    Crisil Ratings upgrades ratings of Gokaldas Exports to 'A+' with 'stable' outlook    Swiggy slides as lock-in period ends 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Granules India rises after arm clears USFDA audit
21-Mar-23   15:00 Hrs IST

The facility was inspected by the US drug regulator from 15 March 2023 to 20 March 2023.

Priyanka Chigurupati, executive director, Granules USA, Inc. & Granules Pharmaceuticals, said, “The audit is a pre-approval inspection for three products filed from the facility. The packaging site strengthens our proposition to control the value chain and provides us with the agility needed in a very dynamic over-the-counter (OTC) space.”

Granules Consumer Health (GCH) is a wholly owned subsidiary of Granules USA, it is a leading private-label OTC provider, and its packaging facility will enable it to service leading retailers more effectively. The packaging facility in Manassas is spread over 79,000 square feet and has several packaging suites to service customer needs.

Granules India is a vertically integrated fast growing Indian pharmaceutical company. It is present across the entire manufacturing value chain - from active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).

The company reported 23.24% jump in net profit to Rs 124.32 crore on a 15% increase in revenue from operations to Rs 1,146.12 crore in Q3 FY23 over Q3 FY22.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 40826506
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd